Emalex eyes FDA approval for Tourette syndrome therapy after Phase III success
The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...
BioSpace8h
Emalex Heads to FDA After Phase III Tourette Syndrome Win
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
The Pharma Letter9h
Emalex Biosciences’ lead candidate Phase III win in Tourette syndrome
Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...
Crain's Chicago Business6h
Chicago pharma gets good news on Tourette syndrome drug candidate
Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...
Medpage Today on MSN7h
'Banned' Words at CDC? House Passes Budget Bill; Measles Outbreak in Texas Expands
CDC staff received an email this week telling them to avoid using more than a dozen terms or words -- including "health ...
pharmaphorum21h
Asarina folds as it ends search for Tourette's drug partner
At the moment, attention is focused on candidates like Emalex Biosciences' ecopipam and Noema Pharma's gemlapodect, both in midstage clinical testing. An extraordinary meeting of shareholders is ...
The Pharma Letter8h
All smiles at GRIN over radiprodil prospects
Neurodevelopmental disorders company GRIN Therapeutics, an affiliate of the Blackstone Life Sciences portfolio company ...